Experienced in Familial Hypertriglyceridemia

Dr. Alexander J. White

Family Medicine
Daytona Beach, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Familial Hypertriglyceridemia
Daytona Beach, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexander White is a primary care provider, practicing in Family Medicine in Daytona Beach, Florida. Dr. White is rated as an Experienced provider by MediFind in the treatment of Familial Hypertriglyceridemia. His top areas of expertise are Alzheimer's Disease, Dementia, Memory Loss, and High Cholesterol.

His clinical research consists of participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Familial Hypertriglyceridemia.

Specialties
Family Medicine
Licenses
Family Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Daytona Beach, FL 32114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drug: TQJ230
Study Phase: Phase 3
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: LY3372993
Study Phase: Phase 1
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug, Other
Study Drug: Bryostatin I
Study Phase: Phase 2
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Drug: Pentosan Polysulfate Sodium
Study Phase: Phase 2/Phase 3
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Other
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 27, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD; #2
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD; #2
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL
Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL
Enrollment Status: Unknown
Publish Date: October 25, 2017
Intervention Type: Biological
Study Drugs: TVGV-1, GPI-0100
Study Phase: Phase 2
View 24 Less Clinical Trials
Similar Doctors
Advanced in Familial Hypertriglyceridemia
Dr. Neil A. Patterson
Family Medicine
Advanced in Familial Hypertriglyceridemia
Dr. Neil A. Patterson
Family Medicine

Ability Health Services And Rehabilitation Lp

1200 Lexington Green Ln, 
Sanford, FL 
 (29.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neil Patterson is a primary care provider, practicing in Family Medicine in Sanford, Florida. Dr. Patterson is rated as an Advanced provider by MediFind in the treatment of Familial Hypertriglyceridemia. His top areas of expertise are Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and High Cholesterol. Dr. Patterson is currently accepting new patients.

Advanced in Familial Hypertriglyceridemia
Dr. Luis E. Morales
Family Medicine
Advanced in Familial Hypertriglyceridemia
Dr. Luis E. Morales
Family Medicine

Town Center Family Practice Inc

1642 N Volusia Ave, 
Orange City, FL 
 (22.0 miles away)
386-774-0188
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Morales is a primary care provider, practicing in Family Medicine in Orange City, Florida. Dr. Morales is rated as an Advanced provider by MediFind in the treatment of Familial Hypertriglyceridemia. His top areas of expertise are High Cholesterol, Familial Hypertriglyceridemia, Infant Hyperglycemia, and Obesity. Dr. Morales is currently accepting new patients.

Advanced in Familial Hypertriglyceridemia
Dr. Gregorio A. Cisneros
Family Medicine
Advanced in Familial Hypertriglyceridemia
Dr. Gregorio A. Cisneros
Family Medicine
17 Old Kings Rd N, Suite J, 
Palm Coast, FL 
 (27.3 miles away)
386-446-4141
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregorio Cisneros is a primary care provider, practicing in Family Medicine in Palm Coast, Florida. Dr. Cisneros is rated as an Advanced provider by MediFind in the treatment of Familial Hypertriglyceridemia. His top areas of expertise are Familial Hypertriglyceridemia, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Hypertension. Dr. Cisneros is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. White's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile